Strategic Partnership Icosavax is part of the AstraZeneca Group, presenting a direct path for collaboration within a large oncology and infectious disease portfolio. Leverage AZ’s global reach and resources to accelerate clinical development and manufacturing scale for vaccine candidates.

Vaccine Platform The company utilizes computationally designed virus-like particle technology, licensed from the Institute for Protein Design. This distinctive platform could be positioned for co-development with CDMO partners and specialized vaccine manufacturers seeking innovative platforms.

Clinical and Market Focus With an emphasis on infectious diseases to reduce healthcare costs, target unmet medical needs, and a focus on vaccines, there are opportunities to align with government vaccination programs, public health initiatives, and strategic disease-area collaborations.

SMB Collaboration Fit Operating with a lean team and moderate revenue, Icosavax may be open to strategic alliances, licensing deals, or sponsored research with larger pharma or specialized biotech players seeking to expand their vaccine pipelines or leverage novel tech in lieu of building in-house capabilities.

Geographic & Manufacturing Leverage Recent AZ-driven expansion plans in the United States and Mexico highlight manufacturing and capability investments. Sales opportunities exist in co-located facilities, regional manufacturing partnerships, and technology transfer arrangements to support global vaccine supply to North America and beyond.